FindTrial
Sign In

Donor lymphocyte infusion for the prophylaxis of relapse in high-risk acute myeloid leukemia patients with AML1/ETO after allogeneic hematopoietic stem cell transplant

Donor lymphocyte infusion for the prophylaxis of relapse in acute myeloid leukemia patients with AML1/ETO after allogeneic hematopoietic stem cell transplant

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-12002891
Enrollment
Unknown
Registered
2012-12-27
Start date
2013-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia patients with AML1/ETO

Interventions

intervention group:prophylactic donor lymphocyte infusion

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 60 Years

Inclusion criteria

Inclusion criteria: High-risk acute myeloid leukemia patients with AML1/ETO undergoing allogeneic hematopoietic stem cell transplant.

Exclusion criteria

Exclusion criteria: 1. Active GVHD; 2. Uncontrolled severe infection; 3. Organ failure; 4. Early relapse or death after HSCT.

Design outcomes

Primary

MeasureTime frame
Rate of relaps after allogeneic hematopoietic stem cell transplant;—

Countries

China

Contacts

Public ContactXiao-Jun Huang
huangxiaojun@bjmu.edu.cn+86 10 88326006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026